S100P and cancer: We suggest that at least some of the genes highlighted here (Tables 2, 3, Cluster1) are centrally involved, not least those that are selective for the drug, such as GLI1, S100P, CLIC3 and NTN4. Previous studies have demonstrated that S100P57,60 is a viable target in human cancers including PDAC, probably by inducing p53-related apoptosis58.